Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)

Trial Profile

A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms BORA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Sep 2023 Results of post hoc analysis of BORA evaluating CR in patients treated with benralizumab for up to 24 months, resented at the 33rd Annual Congress of the European Respiratory Society
    • 29 Aug 2023 According to an AstraZeneca media release, company will present new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from 9-13 September 2023.
    • 17 Feb 2021 Results (n=86) assessing clinical outcomes for adolescents at 2 and 3 years, published in the Journal of Allergy and Clinical Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top